AC Immune reports full-year 2017 financial results

AC Immune (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results and provided a corporate overview for the year ended December 31, 2017, its first full year as a public company.

As quoted in the press release:

Prof. Andrea Pfeifer, CEO of AC Immune, commented: “AC Immune made significant progress in 2017 – our first full year as a public company. Our lead asset, crenezumab, entered a second pivotal Phase 3 trial in Alzheimer’s disease with our partner Genentech. There were important developments with our other assets, and a new collaboration with Essex Biotechnology in Asia. We continue to invest in each of the company’s three strategic pillars – Alzheimer’s disease, neuro-orphan indications and diagnostics – and we believe that precision medicine will significantly improve patients’ lives. During 2017 we were pleased to strengthen our relationships with the investment community. We look forward to sharing some key value inflection points in 2018, like for example the recently announced development of potentially the first selective alpha-synuclein PET tracer for earlier and more accurate diagnosis of Parkinson’s disease.”

Click here to read the full press release.